新发现GRP75-Dbl轴调节Cdc42激活依赖大分子药物内吞研究

批准号:
81373318
项目类别:
面上项目
资助金额:
80.0 万元
负责人:
张思河
依托单位:
学科分类:
H3404.生物技术药物
结题年份:
2017
批准年份:
2013
项目状态:
已结题
项目参与者:
罗娜、张杰、许丽娟、刘赜、田瑞娟、杨楠、何长征、李瑶、Mattias Belting
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
微信扫码咨询
中文摘要
生物大分子穿膜常需伴侣蛋白协助,但后者具体作用机制不明。我们前期发现肿瘤细胞线粒体伴侣蛋白GRP75在Cdc42激活内吞中富集并有调节功能。已知Cdc42 激活受Dbl样RhoGEF催化且后者原癌蛋白受Hsc70介导呈现自抑制。我们后续发现GRP75不与HSPG、Cdc42、Dbl相互作用,只与proto-Dbl结合且位于Dbl上游发挥调节。故提出内吞新调节轴:GRP75-Dbl。本项目拟(1)分析二者调节内吞和相互作用的功能结构域,(2)明确GRP75对proto-Dbl泛素化、成熟和 GEF活性影响,(3)探明GRP75与Hsc70间竞争关系,(4)检测二者亚细胞转位、修饰变化和富集来源,最终阐明GRP75富集通过竞争释放Hsc70对proto-Dbl抑制而激活Cdc42促进大分子内吞机制。这可为Cdc42激活内吞途径上游调节提出新认识,为优化HSPG依赖大分子药物内化递送提供实验支撑
英文摘要
Chaperones are universally recognized for roles in facilitating transmembrane endocytosis of macromolecules. However, underlying mechanism for this process, especially for HSPG-dependent macromolecular drug endocytosis, is unclear. We had showed noticeable enrichment of one chaperone protein, GRP75, which often locates inside mitochondrion, in components of endocytic vesicles of tumor cells. We further provided evidences for its regulatory role in Cdc42 activation-dependent endocytosis of macromolecular drugs such as delivered antibody-Fe nanoparticle, Tat/DNA etc., In tumor cells, it is documented activation of Cdc42 GTPase is dominantly catalyzed by upstream Dbl guanine nucleotide exchange factor (GEF), which proto-form-oncoprotein maintaining an autoinhibitory state by Hsc70-mediated intramolecular attenuation in unstimulated cell. Meanwhile, by direct or indirect protein-protein interaction, translocated GRP75 protein has been implied to facilitate receptor internalization, vesicles/membrane trafficking in different cells. Despite existing some blurry colocalization by cofocal imaging, our co-IP data further showed that GRP75 do not bind to HSPG/HS, GTP/GDP-CDC42 and Dbl, but selectively bind to proto-Dbl protein both in vitro and in vivo. In addition, our further data showed GRP75 acts upstream of Dbl on Cdc42 activation and macromolecule drug endocytosis. Based on these lines, an endocytosis-regulatory axis is emerging, and we reason here macromolecular drug endocytosis stimulates enrichment of GRP75, which promotes Cdc42 activation-dependent endocytosis by competitively release of Hsc70 from autoinhibitory proto-Dbl protein. Therefore, we propose to focus research topic on endocytosis regulatory role of GRP75-proto-Dbl interaction. One series experiments are designed to pursuit functional domain(s) determining Cdc42 activation and macromolecular drug endocytosis. another series experiments aim to find key domain(s) mediate GRP75-proto-Dbl functional interaction and downstream changes of Cdc42 activation level correspondingly. Stem experiments are designed to check the competition relationship to Proto-Dbl protein between GRP75 and Hsc70, and to detect ubiquitination and degradation changes of proto-Dbl by overexpression and down-regulation/interference of GRP75. Last but not least, certain experiments are settled to check subcellular location, dynamic translocation and cell surface enrichment of GRP75 and Dbl protein. Combined with these data, it would uncover endocytosis regulatory mechanism of GRP75 and intermolecular functional association of GRP75-Dbl axis. Once approved and done, it would challenge traditional knowledge on chaperone protein, present novel insight into upstream regulation of Cdc42 activation-dependent endocytosis. It will also be great benefited for optimization of HSPG-dependent macromolecular drug endocytic delivery strategy.
生物大分子药物穿膜内吞常需伴侣蛋白协助,但后者具体作用机制不明。我们研究发现,线粒体伴侣蛋白GRP75在Cdc42激活HSPG依赖内吞囊泡中富集并有调节功能,提示GRP75可通过蛋白相互作用参与膜转运过程。Cdc42 激活受Dbl样Rho-GEF催化,而后者原癌蛋白受胞质Hsc70介导呈现自抑制状态。我们进一步发现,GRP75并不与HSPG、Cdc42和Dbl相互作用,只与未降解proto-Dbl结合且GRP75位于Dbl上游调节Cdc42激活和大分子内化。因此我们提出,大分子药物内吞可能受一个新调节轴GRP75-Dbl调节。本项目研究结果亮点有5个:(1) 发现肿瘤细胞线粒体动态转运GRP75向囊泡富集可通过共激活Cdc42和RhoA介导的细胞骨架重组,促进非网格蛋白内吞途径但同时抑制网格蛋白内吞途径。(2) 新发现GRP75具有调节细胞内吞和调控细胞周期的兼差功能,为靶向乏氧肿瘤微环境的细胞内吞递送纳米微球药物提供了新的可能。(3) 构建了不同形式GRP75、proto-Dbl结构域突变体,为分析二者激活Cdc42、调节内吞的功能奠定了基础;(4) 发现抑制GRP75可削弱proto-Dbl蛋白泛素化成熟降,GRP75的囊泡富集可通过竞争释放Hsc70对proto-Dbl抑制继而激活Cdc42促进大分子内吞。(5) 另外,我们还通过噬菌体抗体库技术筛选到1株特异结合乏氧肝癌细胞的单链抗体。所有这些,可为Cdc42激活的内吞途径上游调节提出新认识,为优化HSPG依赖大分子药物内化递送提供实验支持和必备工具。
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
Clinical prognostic factors for time to positivity in cancer patients with bloodstream infections
血流感染癌症患者阳性时间的临床预后因素
DOI:10.1007/s15010-016-0890-2
发表时间:2016-10-01
期刊:INFECTION
影响因子:7.5
作者:Zhang, Qing;Li, Ding;Zhang, Sihe
通讯作者:Zhang, Sihe
Mitochondria chaperone GRP75 moonlighting as a cell cycle controller to derail endocytosis provides an opportunity for nanomicrosphere intracellular delivery.
线粒体伴侣 GRP75 兼职作为细胞周期控制器来破坏内吞作用,为纳米微球细胞内递送提供了机会
DOI:10.18632/oncotarget.17234
发表时间:2017-08-29
期刊:Oncotarget
影响因子:--
作者:Gao Z;Niu X;Zhang Q;Chen H;Gao A;Qi S;Xiang R;Belting M;Zhang S
通讯作者:Zhang S
Phage display library selection of a hypoxia-binding scFv antibody for liver cancer metabolic marker discovery.
用于肝癌代谢标志物发现的缺氧结合 scFv 抗体的噬菌体展示文库选择
DOI:10.18632/oncotarget.9460
发表时间:2016-06-21
期刊:Oncotarget
影响因子:--
作者:Liu J;Zhang Q;Chen H;Gao Z;Li Y;Sun Z;Xiang R;Zhang S
通讯作者:Zhang S
Bacteraemia due to AmpC beta-lactamase-producing Escherichia coli in hospitalized cancer patients: risk factors, antibiotic therapy, and outcomes
住院癌症患者中由产 AmpC β-内酰胺酶的大肠杆菌引起的菌血症:危险因素、抗生素治疗和结果
DOI:10.1016/j.diagmicrobio.2017.04.006
发表时间:2017
期刊:Diagnostic Microbiology and Infectious Disease
影响因子:2.9
作者:Zhang Qing;Zhang Wenfang;Li Zheng;Bai Changsen;Li Ding;Zheng Shan;Zhang Peng;Zhang Sihe
通讯作者:Zhang Sihe
DOI:10.13423/j.cnki.cjcmi.007907
发表时间:2016
期刊:细胞与分子免疫学杂志
影响因子:--
作者:陈航;牛秀然;高嫒嫒;张思河
通讯作者:张思河
国内基金
海外基金
